A5046176418- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Ovarian cancer diagnosis and treatment
- COVID-19 and healthcare impacts
- Renal cell carcinoma treatment
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Drug Transport and Resistance Mechanisms
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Inflammatory Biomarkers in Disease Prognosis
- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- SARS-CoV-2 and COVID-19 Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cutaneous Melanoma Detection and Management
- Gastrointestinal Tumor Research and Treatment
- Cancer, Hypoxia, and Metabolism
Australian National University
2007-2024
Canberra Hospital
2014-2024
Princess Margaret Cancer Centre
2017-2022
University Health Network
2017-2022
Monash Health
2022
ACT Government
2016-2021
Peter MacCallum Cancer Centre
2016-2019
University of Toronto
2017-2019
Prince of Wales Hospital
2018-2019
Act Health
2014
Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough is its potential achieve durable responses in a subset patients advanced cancer can be maintained several years even after stopping the treatment. No standardized definition exists literature, optimal duration treatment case clearly established. However, majority do respond immunotherapy. Initially melanoma...
A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) in comparison pretreatment kinetics; this is known as hyperprogression. This study assessed the relation between hyperprogressive disease (HPD) and treatment-related toxicity clinical factors.This reviewed solid tumors who were enrolled early-phase immunotherapy trials at Princess Margaret Cancer Centre August 2012 September 2016 had computed tomography scans pre-immunotherapy...
Abstract Denosumab, an anti‐resorptive treatment for osteoporosis and skeletal metastases from solid tumours, can cause hypocalcaemia. The incidence may be higher than previously reported due to varying serum calcium cut‐off timing of measurement. following cases illustrate patients at risk hypocalcaemia despite supplementation. These populations, with underlying high bone turnover metastatic disease or secondary hyperparathyroidism renal failure, require closer monitoring levels...
Immune checkpoint inhibitors (ICI) are increasingly used in cancer therapy. Elevated liver enzymes frequently occur patients treated with ICI but evaluation is poorly described. We sought to better understand causes of enzyme elevation, investigation and management.
Solid tumor malignancy (STM) patients experience increased risk of breakthrough SARS-CoV-2 infection owing to reduced COVID-19 vaccine immunogenicity. However, the underlying immunological causes impaired neutralization remain poorly characterized. Furthermore, non-neutralizing antibody functions can contribute disease severity but understudied within high-risk populations. We dissected polyfunctional responses in STM and age-matched controls who received adenoviral vector- or mRNA- based...
ABSTRACT The risk of infection in patients receiving immune checkpoint inhibitor (ICI) therapy is not well understood. Immune‐related adverse events requiring immunosuppressive may impact risk. ICIs induce an exaggerated response to latent infection. We assessed the incidence and factors for infections during cancer ICI therapy. A retrospective chart review solid tumor treated with was conducted. Infectious episodes were defined as those where a microbial organism cultured or identified...
Background:To investigate the effect of folic acid on increased pressure in rats treated with either adrenocorticotropic hormone (ACTH) or dexamethasone (Dex), and to further role tetrahydrobiopterin (BH4) any by comparing BH4 that Dex hypertension.
The role of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) in the era targeted therapies is currently undefined. In recent years, neutrophil-to-lymphocyte ratio (NLR) has emerged as a prognostic marker several cancers, including mRCC. this multicentre retrospective study, we aim to assess impact CN mRCC and value NLR risk stratification patient selection.Retrospective data from patients with de novo four large Australian hospitals were collected. Survival analyses...
Objective To examine the patterns of care and outcomes for metastatic renal cell carcinoma ( mRCC ) in A ustralia, where there are limited reimbursed treatment options. In particular, we aim to explore prescribing first‐line systemic treatment, practice an initial watchful‐waiting approach, use treatments elderly patients. Subjects/Patients Methods Patients with undergoing between 2006 2012 were identified from four academic hospitals V ictoria ustralian C apital T erritory. Demographic,...
Aim Benefit of adjuvant imatinib therapy following curative resection in patients with intermediate-risk gastrointestinal stromal tumor (GIST) is unclear. GIST-specific exon mutations, particular 11 deletions, have been shown to be prognostic. We hypothesize that specific KIT mutations may improve risk stratification GIST, identifying a subgroup who benefit from therapy. Methods In total, 142 GIST complete clinicopathologic and mutational data two sites were included. Risk classification was...
Abstract Background Cancer patients have increased morbidity and mortality from COVID‐19, but may respond poorly to vaccination. The Evaluation of COVID‐19 Vaccination Efficacy Rare Events in Solid Tumors (EVEREST) study, comparing seropositivity between cancer healthy controls a low SARS‐CoV‐2 community‐transmission setting, allows determination vaccine response with minimal interference infection. Methods tumor Canberra Hospital, Canberra, Australia, who received vaccination March 2021...
Cisplatin is a widely used chemotherapeutic agent for many cancer types. Its toxicity profile includes drug-induced vascular damage. Clinicians should be aware of its varied presentation, including acute and chronic events involving the arterial venous system. This case an otherwise well 32-year-old man with testicular who received bleomycin/etoposide/cisplatin, presented following two cycles chemotherapy homonymous hemianopia secondary to stroke. Acute complications are rare, but clinicians...
Abstract People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID‐19). COVID‐19 vaccination is key protecting population of people adverse outcomes SARS‐CoV‐2 infection. The Medical Oncology Group Australia aimed address considerations around in cancer, particular, safety efficacy vaccination. assessment patients generalised allergic reaction anti‐cancer therapy containing vaccine components practical implementation on active also discussed.
5522 Background: CCOC is a rare chemoresistant subtype of OC. ENMD-2076 an oral multi-target kinase inhibitor with antiangiogenic/antiproliferative profile; selective activity against the mitotic Aurora A and VEGFRs, FGFRs. Methods: This multi-center Phase II study in pts recurrent prior platinum. Primary endpoints were ORR 6-m PFS rate. Correlative analyses include ARID1A, PTEN expression by IHC genome sequencing custom capture library 555 genes. Results: Completed enrolled 40 – 37...
Immuno-oncology (IO) is rapidly evolving in early drug development. We aimed to develop and prospectively validate a prognostic index for patients treated IO phase I trials assist with patient selection.The development cohort included 192 advanced solid tumor 13 trials, targeting immune checkpoint and/or co-stimulatory molecules. A scoring system was developed from multivariate survival analysis of 10 clinical factors, subsequently validated two independent validation cohorts (n = 152 n...
3063 Background: A subset of patients (pts) treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) compared pre-treatment kinetics, known as hyperprogression. The aim this study was to explore the relationship between HPD, treatment-related toxicity and clinical factors. Methods: Consecutive pts enrolled in early-phase trials involving and/or costimulatory molecules at Princess Margaret Cancer Centre 8/2012 – 9/2016 CT scans available for RECIST 1.1...